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Abstract
Introduction: Verbal fluency is the ability to form and express words compatible
with required criteria. Verbal fluency is necessary for optimal communication
and for normal social and occupational functioning. The Verbal Fluency Test is
a good indicator of frontal lobe dysfunction, particularly of the left frontal cortex.
Material and methods: The aim of the study was to compare verbal fluency in
healthy subjects (n = 50), patients with paranoid schizophrenia (n = 36), patients
with organic lesions of the central nervous system (CNS) (n = 33), and patients
with diabetes (n = 62) – type 1 diabetes (n = 31) and type 2 diabetes (n = 31).
Results: Healthy subjects and patients with diabetes achieved the highest results
in all categories of the Verbal Fluency Test. Patients with paranoid schizophrenia
achieved significantly lower results. Sten norms of the Verbal Fluency Test were
developed for the general population. Using these norms it was found that
subjects with schizophrenia or with organic lesions of the CNS had very poor
results more often and very high results less frequently compared to healthy
subjects and also to patients with diabetes.
Conclusions: This observation is consistent with the neurodevelopmental
hypothesis of schizophrenia, in which cognitive functions of the frontal lobe
(e.g. verbal fluency) play a major role in the psychopathological picture. We have
also demonstrated that in patients with type 1 and 2 diabetes verbal fluency is
comparable with healthy subjects.
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Introduction
Verbal fluency is defined as the ability to form and express words in
accordance with required criteria. Disorders of verbal fluency may take the
form of verbal perseverations or forming words that do not belong to
a required category. A normal level of verbal fluency is necessary for
optimal communication and, therefore, for normal social and occupational
functioning. The Verbal Fluency Test is a commonly accepted and widely
applied test, used for assessing verbal fluency. The reliability of this test
has been demonstrated by other authors and a high level of internal
coherence was found (r-Pearson = 0.85) [1]. The number of words in each
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category is consistent with the efficacy of all
aspects of the studied variable (the higher the
result, the higher the efficacy of these functions).
The results of the Verbal Fluency Test are a good
diagnostic indicator of frontal lobe dysfunction [2].
The Verbal Fluency Test, similarly to other tests that
assess executive functions (Wisconsin Card Sorting
Test, Trail Making Test), is a sensitive tool, which
enables one to detect dysfunctions of the frontal
lobes, particularly of the left frontal cortex [3]. Poor
results of the Verbal Fluency Test may also be
associated with dysfunctions of the temporal cortex
and prefrontal cortex of the left hemisphere. Area 44
and 45 situated within the inferior frontal gyrus
(Broca’s region) and dorsolateral prefrontal cortex of
the left hemisphere are activated while performing
this test [4]. The inferior part of the left prefrontal
cortex is activated while executing the letter test,
while the anteroinferior part of the prefrontal cortex
is activated while executing the category test [5]. 
Disorders of cognitive functions, including
executive functions, for example verbal fluency, are
often present in subjects with schizophrenia.
Disorders of the working memory and executive
functions are the fundamental and established
deficit, which may become intensified in the course
of the disease [6]. This has a significant effect on
the efficacy of other cognitive functions and
determines adaptability of patients. These deficits
are present before the onset of schizophrenia and
become more intense during the first episode of
schizophrenia. Their presence before the onset of
symptomatic psychosis supports the neuro  -
developmental hypothesis of schizophrenia,
according to which genetic and environmental
factors take part in the aetiopathogenesis of this
disease. Interactions of these factors at early stages
of the development of the central nervous system
may have disadvantageous effects on neuron
growth and cytoarchitectonics of the brain cortex.
These abnormalities develop during fetal
development and early childhood and are expressed
in the form of schizophrenia after puberty [7]. They
are significantly more intense in patients who did
not undergo medical treatment during the first
period of psychosis. Longer duration of untreated
psychosis is associated with higher risk of
permanent global cognitive deficits [8]. Disorders
of verbal functions in subjects with schizophrenia
are strictly associated with disorders of information
processing processes, executive functions and
memory processes. They are present in subjects
with schizophrenia in the prodromal period, 
as well as in their first-degree relatives. The latter
observation is consistent with the neuro  -
developmental hypothesis of schizophrenia.
Decreased verbal fluency in this group of patients
is expressed in the form of numerous
perseverations, neologisms and listing words that
do not belong to a required category [9].
Patients with diabetes are a group in which
involutive processes occur earlier and progress
faster (this also applies to cognitive functioning)
[10]. In the group of patients aged > 60 years
a significant decline of cognitive functions
compared to healthy subjects was found 4 years
after diagnosis of diabetes [11]. Strachan et al. [12]
found that cognitive disorders are more frequent
in patients with diabetes than in subjects at the
same age without diabetes. Also in patients with
an abnormal glucose curve (but without
symptomatic diabetes) increased frequency of mild
cognitive disorders was found [13]. According to
other authors [14] diabetes increases the risk of
dementia (both vascular and Alzheimer’s) two-fold.
Cukierman et al. [15] suggested that cognitive
disorders should be included in the group of chronic
complications of diabetes. Diabetes (type 1 and 2)
causes disorders of verbal and spatial memory,
efficacy of attention processes, verbal fluency and
functions that depend on the frontal lobes
(associative functions), and psychomotor dexterity,
and is associated with increased risk of intellectual
disorders [16-20]. 
The objective of this research was to evaluate
verbal skills in a group of healthy subjects, patients
with paranoid schizophrenia, patients with type 1
and 2 diabetes, and patients with diagnosed
organic lesions of the central nervous system (CNS).
On the basis of the results the authors carried out
normalization of the Verbal Fluency Test. The
authors have developed a sten scale which enables
psychologists and psychiatrists to assess
qualitatively the results of the Verbal Fluency Test.
Moreover, the presence of normalization allows
researchers to compare obtained results with
a reference group (the general population).
Material and methods
One hundred and eighty-one subjects (men 
n = 105 [58.01%]) aged 18-55 years participated in
the study. Mean age of all studied subjects was
38.37 ±12.18 years. The participants of the study
were divided into 6 groups: healthy subjects 
(n = 50; men n = 25 [50.0%]; mean age 31.52 ±9.30
years), patients with paranoid schizophrenia 
(n = 36; men n = 27 [75.0%]; mean age 35.83 ±13.87
years), patients with diagnosed organic lesions of
the CNS (n = 33; men n = 22 [66.7%]; mean age
43.91 ±11.23 years), patients with diabetes (n = 62;
men n = 31 [50.0%]; mean age 42.42 ±10.78 years),
who were divided into two subgroups: patients with
type 1 diabetes (n = 31; men n = 8 [25.5%]; mean
age 38.10 ±11.64 years) and patients with type 2
diabetes (n = 31; men n = 23 [74.2%]; mean age
46.74 ±7.88 years). 
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Exclusion criteria for the schizophrenia group
were: the presence of any organic lesions of the
central nervous system and coexisting somatic
diseases, including diabetes. Exclusion criteria for
the CNS lesion group were: the presence of somatic
diseases, including diabetes, and diagnosis of
schizophrenia or other schizophrenia-like psychoses.
Exclusion criteria for the combined diabetes group
(and therefore for type 1 and type 2 groups) were:
the presence of organic lesions in the central
nervous system, schizophrenia or other
schizophrenia-like psychoses. Mean PANSS score
in the group of schizophrenic patients was 68.67
±28.83 points. Treatment duration in that group was
≥ 4 weeks (mean 72.07 ±42.68 weeks). The patients
in that group were treated with typical and atypical
antipsychotics. The numbers of patients treated
with individual antipsychotics were small and
therefore these variables were excluded from
further analysis. Central nervous system lesions
were diagnosed on the basis of neuroimaging
examinations (computer tomography and/or
magnetic resonance imaging) and neuropsycho  -
logical examination carried out before the study.
Treatment duration in the combined group of
patients with diabetes, type 1 diabetes and type 2
diabetes were 158.52 ±122.92, 176.13 ±162.05, and
140.90 ±61.81 weeks, respectively. Mean glycated
haemoglobin (HbA1c) levels in the combined group
of patients with diabetes, type 1 diabetes and type 2
diabetes were 9.47 ±2.69, 9.17 ±1.46, and 9.78
±3.56%, respectively. All patients were examined
for the presence of mood disorders. Only patients
without depression and mania were included in the
study groups. Participants of the study had no IQ
test carried out; however, none of the patients had
mental retardation diagnosed before participating
in the study. Academic level of the study
participants is presented in Table I. The authors did
not normalize the results for individual academic
levels as the number of subjects for these
subgroups was too small. The patients were treated
in accordance with current guidelines for individual
diseases and the authors did not intervene in the
therapeutic process. Each participant gave written
informed consent. The study protocol was
authorized by the ethics committee of the Medical
University of Lodz.
The Verbal Fluency Test was used in the study.
This test evaluates the ability to form and fluently
utter words compatible with given criteria. The test
consists of three parts. The first two parts consist
in listing in 60 s as many words as possible that
belong to a given semantic category (usually names
of objects). In the third part the objective is to list
in 60 s as many words as possible that belong to
a given phonetic category – words beginning with
a given letter. In the present study these categories
were: names of animals (category 1), names of
sharp objects (category 2) and words beginning
with the letter K (category 3). The result of the test
is the number of correct words listed for each of
the categories.
Obtained results were analysed statistically using
ANOVA method and post-hoc tests. Statistical
analysis was carried out using STATISTICA 7.0 PL
software.
Results
Detailed results of the Verbal Fluency Test for
individual categories are presented in Table II. Using
the Levene test of uniform variances it was found
that all groups are unified in terms of analysed
variables – p-values for category 1, 2 and 3 were
0.055, 0.725 and 0.472, respectively. To evaluate
differences between average results achieved by
subjects in each category ANOVA analysis was
used. The analysis revealed statistically significant
differences of means between individual groups for
each Verbal Fluency Test category: names of
animals: F = 11.056, df = 5, p < 0.0001; names of
sharp objects: F = 6.497, df = 5, p < 0.0001; words
beginning with the letter K: F = 9.931, df = 5, 
p < 0.0001. 
Obtained results were analysed using the post-
hoc Scheffe test in order to evaluate the presence
of statistically significant differences between
individual groups. For category 1 (“names of
animals”) we found that the lowest results were
achieved in the groups of patients with
schizophrenia and with CNS lesions (p < 0.05 vs.
healthy subjects, patients with type 1 diabetes and
combined diabetes group). There were no
significant differences between the results of
GroupP rimary  Secondary Higher
or vocational n (%) n (%)
n (%)
Healthy subjects 4 (8.0%) 22 (44.0%) 24 (48.0%)
(n = 50)
Schizophrenia 11 (30.6%) 21 (58.3%) 4 (11.1%)
(n = 36)
CNS lesions 14 (42.4%) 16 (48.5%) 3 (9.1%)
(n = 33)
Diabetes 19 (30.7%) 33 (53.2%) 10 (16.1%)
(n = 62)
Type 1 6 (19.4%) 19 (61.3%) 6 (19.3%)
(n = 31)
Type 2 13 (41.9%) 14 (45.2%) 4 (12.9%)
(n = 31)
Total 48 (26.5%) 92 (50.8%) 41 (22.6%)
(n = 181)
Table I. Academic level of the study participants
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healthy subjects and patients with diabetes or
between patients with type 1 and type 2 diabetes.
The results of patients with type 2 diabetes did not
significantly differ from the results of patients with
schizophrenia or CNS lesions. For category 2
(“names of sharp objects”) we found that the
results of patients with schizophrenia were
significantly lower (p < 0.05) than those of healthy
subjects, patients with type 1 and type 2 diabetes
and the combined diabetes group. The results of
patients with CNS lesions were significantly lower
(p < 0.05) than those of healthy subjects, but not
schizophrenic or diabetic patients (or type 1 and
type 2 diabetes subgroups). Again, there were no
significant differences between the results of
healthy subjects and patients with diabetes or
between patients with type 1 and type 2 diabetes.
For category 3 (“words beginning with the letter K”)
the results were similar to those observed for
category 1. The only difference was that the results
for patients with type 2 diabetes were also
significantly higher (p < 0.05) than those for
patients with schizophrenia or CNS lesions. Figures
1-3 present the values of the median, 25-75% range
and min-max for individual categories of the Verbal
Fluency Test for all studied groups. 
On the basis of obtained results the authors
developed a sten scale for each category of 
the Verbal Fluency Test. The sten (standard ten)
scale is a scale of the following characteristics:
mean = 5.5, standard deviation = 2.0. It has ten
items (stens). Each item represents 0.5 standard
deviation and a certain percentage of the area
under the curve of the normal distribution of
results. Items 1-2 represent very low results; 
3-4 – low results; 5-6 – average results; 7-8 – high
results; and 9-10 – very high results. 
Raw scores for each category of the Verbal
Fluency Test were transformed statistically. First,
we calculated the cumulative number of patients
for each score (cf). Next, cf values were multiplied
by 1/n (n = 181). Then, the results were transformed
into sten scores using the transformation table
described in [21]. Developed sten scores are
presented in Table III. Using this table it is possible
to convert raw results for each category into sten
scores. Subsequently, these scores may be
described qualitatively. This makes describing
observed results easier and clearer. Moreover, using
sten scores it is possible to make qualitative
comparisons between different populations. Using
the developed sten scale we have analysed the
results obtained for individual categories of the
Verbal Fluency Test. Appropriate sten scores were
attributed to individual patients’ results on the basis
of the developed sten scale. Next, the number of
patients from individual groups who achieved the
same sten score for a particular category was
analysed. This enabled us to compare sten scores
of the studied groups. Figures 4-5 present the
number of subjects from each studied group for
individual values of the sten scale. 
Discussion
Healthy subjects and patients with diabetes
(type 1 and 2) achieved the highest results in all
categories of the Verbal Fluency Test. In the case
of patients with paranoid schizophrenia and
patients with organic lesions of the CNS the results
obtained by these patients were compatible with
GroupN ames of animals Names of sharp objects Words beginning with the letter K
Mean SD Range Mean SD Range Mean SD Range
Healthy subjects 26.44 8.73 11-45 13.18 4.27 5-21 19.08 6.59 8-37
(n = 50)
Schizophrenia 16.69 3.39 7-30 8.72 3.62 1-17 13.39 4.84 1-21
(n = 36)
CNS lesions 16.91 5.66 7-28 9.33 4.24 3-21 12.76 5.96 3-33
(n = 33)
Diabetes 22.87 7.64 11-42 11.64 5-23 4.18 18.79 5.66 5-31
(n = 62)
Type 1 24.32 7.71 13-42 11.71 4.06 5-23 19.19 5.23 9-31
(n = 31)
Type 2 21.42 7.41 11-41 11.58 4.36 6-21 18.39 6.13 5-29
(n = 31)
Total 21.54 8.37 7-45 11.07 4.43 1-23 16.70 6.46 1-37
(n = 181)
Table II. Results of the Verbal Fluency Test
SD – standard deviation, CNS – central nervous system
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the results published in other papers. There were
no statistically significant differences in the results
for category 1 (names of animals), category 2
(names of sharp objects) and category 3 (words
beginning with the letter K) between the group of
patients with schizophrenia and patients with
organic lesions of the CNS. In all three categories
of the Verbal Fluency Test the patients belonging
to these two groups (patients with schizophrenia
and with organic lesions) obtained significantly
lower results than did healthy subjects or, what is
more interesting, patients with diabetes. Patients
in these two groups obtained very low results more
often and very high results less frequently for each
of the three categories compared to other
participants of the study. 
In the case of patients with paranoid
schizophrenia and with organic lesions of the CNS
Sten Number of words Sten
Category 1 Category 2 Category 3
(names of animals)( names of sharp objects)( words beginning with the letter K)
1 ≤ 8 ≤ 3 ≤ 41
2 9-10 4-5 5-6 2
3 11-12 6 7-10 3
4 13-15 7-8 11-13 4
5 16-20 9-10 14-17 5
6 21-25 11-12 18-19 6
7 26-29 13-15 20-23 7
8 30-36 16-18 24-26 8
9 37-40 19-20 27-29 9
10 > 40 > 20 > 29 10
Table III. Sten norms for individual categories of the Verbal Fluency Test
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Figure 1. Median, 25-75% range, min-max for Verbal
Fluency Test category 1 (names of animals)
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Group 1 – healthy subjects, group 2 – subjects with schizophrenia, 
group 3 – subjects with organic lesions of the central nervous system,
group 4 – subjects with diabetes (type 1 and 2), group 5 – subjects with
type 1 diabetes, group 6 – subjects with type 2 diabetes
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Group 1 – healthy subjects, group 2 – subjects with schizophrenia, 
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type 1 diabetes, group 6 – subjects with type 2 diabetes
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Figure 3. Median, 25-75% range, min-max for Verbal
Fluency Test category 3 (words beginning with the
letter K)
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Group 1 – healthy subjects, group 2 – subjects with schizophrenia, 
group 3 – subjects with organic lesions of the central nervous system,
group 4 – subjects with diabetes (type 1 and 2), group 5 – subjects with
type 1 diabetes, group 6 – subjects with type 2 diabetes
Figure 2. Median, 25-75% range, min-max for Verbal
Fluency Test category 2 (names of sharp objects)
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Figure 4. Sten results for Verbal Fluency Test category 1 (names of animals)
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Figure 5. Sten results for Verbal Fluency Test category 2 (names of sharp objects)
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Figure 6. Sten results for Verbal Fluency Test category 3 (words beginning with the letter K)
the results for all three categories were significantly
lower than the results of healthy subjects. In the
case of category 1 the results were also lower than
the results achieved by patients with diabetes and
the results obtained in the subgroup of type 1
diabetes patients. Moreover, in these subgroups
the results in category 3 were also lower than the
results of the patients with type 2 diabetes. Such
differences were not observed for category 2, except
for a statistically significant difference between the
group of patients with paranoid schizophrenia and
the group of patients with diabetes.
We found no statistically significant differences
between healthy subjects and patients with
diabetes or between individual subgroups of
patients with diabetes (type 1 and type 2). On the
basis of published papers on that subject,
a conclusion may be drawn that in general
researchers do not agree on the extent and type of
cognitive deficits that may result from diabetes (for
example Lobnig et al. [22] emphasize the presence
of non-significant differences in verbal fluency in
both types of diabetes [type 1 and type 2], while
Hsu-Ko Kuo et al. [23] report that the speed of
mental processes is reduced in patients with
diabetes). According to Arvanitakis et al. [16],
Audenaert  et al. [24], Kumari et al. [25], and
Manschot  et al. [18] type 2 diabetes causes
disorders of verbal and spatial memory, verbal
fluency, function of the frontal lobe (associative and
executive functions), and psychomotor abilities,
and is associated with increased risk of intellectual
disorders. On the other hand, Wysocki et al. [26]
and Brands et al. [27] claim that the episodes of
hypoglycaemia, which are more frequent among
patients with type 1 diabetes, may lead to the
deterioration of cognitive functions, but these
changes are usually short-lasting and transitory.
Yeung et al. [28] reported that there are no changes
of verbal fluency in the course of diabetes, while
Gallacher et al. [29] and Kanaya et al. [30] reported
the presence of negative effects of diabetes on the
efficacy of verbal fluency. Our results seem to
confirm the former observation.
In conclusion, patients with paranoid
schizophrenia and subjects with organic lesions of
the central nervous system achieved significantly
lower scores in the Verbal Fluency Test compared
to healthy subjects and patients with diabetes (both
type 1 and type 2). The results of subjects with
paranoid schizophrenia did not statistically differ
from those of subjects with organic lesions of the
CNS. No significant differences were found in the
results of the Verbal Fluency Test between healthy
subjects and patients with diabetes.
On the basis of obtained results the authors
developed sten norms of the Verbal Fluency Test
for the general population. Using these norms the
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authors found that subjects with paranoid
schizophrenia or with organic lesions of the central
nervous system had very poor results more often
and very high results less frequently than did
healthy subjects or patients with diabetes. Such
differences were not found in the case of patients
with diabetes. However, it should be noticed that
the developed norms are still hypothetical and
therefore the results obtained using these norms
require further studies, to confirm the observed
differences. 
The obtained results confirm the presence of
significant deficits of verbal fluency in patients with
paranoid schizophrenia, whose magnitude is at
least comparable to that found in patients with
organic lesions of the central nervous system.
Moreover, we have found that patients with
diabetes (type 1 and 2) achieve results in the Verbal
Fluency Test that are comparable with healthy
subjects; therefore, it may be assumed that
cognitive dysfunctions that are described in that
population do not include disturbances of verbal
fluency.
Acknowledgments
This study was supported by the Medical
University of Lodz, grant no. 502-15.644.
References
1. Vlaar A, Wade D. Verbal fluency assessment of patients
with multiple sclerosis: test – retest and inter-observer
reliability. Clin Rehabil 2003; 17: 756-64.
2. Baldo JV, Schwartz S, Wilkins D, Dronkers NF. Role of
frontal versus temporal cortex in verbal fluency as
revealed by voxel-based lesion symptom mapping. J Int
Neuropsychol Soc 2006; 12: 896-900.
3.  Gouveia PA, Brucki SM, Malheiros SM, Bueno OF.
Disorders in planning and strategy application in frontal
lobe lesion patients. Brain Cogn 2007; 63: 240-6. 
4.  Oades RD, Bender S, Müller B, Sartory G. Neuro  -
psychological indicators of heteromodal cortex (dys)
function relevant to conditioned blocking measures of
attention in schizophrenia. Cognit Neuropsychiatry 2001;
6: 41-61.
5. Gaillard W, Hertz-Pennier L, Mott S, Barnett A, LeBihan D,
Theodore W. Functional anatomy of cognitive
development: fMRI of verbal fluency in children and
adults. Neurology 2000; 54: 180-8.
6. Volz HP, Gaser C, Häger F, et al. Brain activation during
cognitive stimulation with the Wisconsin Card Sorting
Test – a functional MRI study on healthy volunteers and
schizophrenics. Psych Res 1997; 75: 145-57.
7. Lipska BK, Weinberger DR. A neurodevelopmental model
of schizophrenia: neonatal disconnection of the
hippocampus. Neurotox Res 2002; 4: 469-75.
8. Bottlender R, Sato T, Jäger M, et al. The impact of the
duration of untreated psychosis prior to first psychiatric
admission on the 15-year outcome in schizophrenia.
Schizophr Res 2003; 62: 37-44.
9. Meilijson SR, Kasher A, Elizur A. Language performance
in chronic schizophrenia: a pragmatic approach. J Speech
Lang Hear Res 2004; 47: 695-713.
10. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman
WH. Impact of diabetes on cognitive function among older
Latinos: a population-based cohort study. J Clin Epidemiol
2003; 56: 686-63.
11. Fontbonne A, Berr C, Ducimetie `re P, Alpérovitch A. Changes
in cognitive abilities over a 4-year period are unfavorably
affected in elderly diabetic subjects: results of the
Epidemiology of Vascular Aging Study. Diabetes Care 2001;
24: 366-70.
12. Strachan MW, Deary IJ, Ewing FM, Frier BM. Recovery of
cognitive function and mood after severe hypoglycemia
in adults with insulin-treated diabetes. Diabetes Care
2000; 23: 305-12.
13. Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive
function in an elderly population with persistent impaired
glucose tolerance. Diabetes Care 1998; 21: 398-402.
14. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A,
Breteler MM. Diabetes mellitus and the risk of dementia:
The Rotterdam Study. Neurology 1999; 53: 1937-42.
15. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline
and dementia in diabetes – systematic overview of
prospective observational studies. Diabetologia 2005; 48:
2460-9.
16. Arvanitakis Z, Wilson RS, Li Y, Aggarwal NT, Bennett DA.
Diabetes and function in different cognitive systems in
older individuals without dementia. Diabetes Care 2006;
29: 560-5.
17. Awad N, Gagnon M, Messier C. The relationship between
impaired glucose tolerance, type 2 diabetes, and cognitive
function. J Clin Exp Neuropsychol 2004; 26: 1044-80.
18. Manschot SM, Brands AM, van der Grond J, et al. Utrecht
Diabetic Encephalopathy Study Group. Brain magnetic
resonance imaging correlates of impaired cognition in
patients with type 2 diabetes. Diabetes 2006; 55: 1106-13.
19. Talarowska M, Florkowski A, Gałecki P, Orzechowska A,
Janiak M, Zboralski K. Zaburzenia funkcji poznawczych
wśród chorych na cukrzycę [Polish]. Pol Merkuriusz Lek
2008; 15: 349-55.
20. Talarowska M, Florkowski A, Orzechowska A, Wysokiński A,
Zboralski K. Funkcjonowanie poznawcze chorych na
cukrzycę typu 1 i 2 [Polish]. Diabetol Prakt 2008; 9: 3-8.
21. Canfield A. The “sten” scale – a modified C-scale. Educ
Psychol Measure 1951; 11: 295-7.
22. Lobnig B, Krömeke O, Optenhostert-Porstt C. Hippocampal
volume and cognitive performance in long-standing type
1 diabetic patients without macrovascular complications.
Diabet Med 2005; 23: 32-9.
23. Hsu-Ko Kuo, Jones R, Milberg W. Effect of blood pressure
and diabetic mellitus and cognitive and physical functions
in older adults: a longitudinal analysis of the advanced
cognitive training for independent and vital elderly cohort.
J Am Geriatr Soc 2005; 53: 1154-61.
24. Audenaert K, Lahorte P, Brans B, et al. The classical Stroop
interferencje task as a prefrontal activation probe:
a validation study using 99Tc m-ECD brain SPECT. Nucl
Med Commun 2001; 22: 135-43.
25. Kumari M, Brunner E, Fuhrer R. Minireview: mechanisms
by which the metabolic syndrome and diabetes impair
memory. J Gerontol A Biol Sci Med Sci 2000; 55: 228-33.
26. Wysocki T, Harris M, Mauras N, Taylor A, Jackson S, White N.
Absence of adverse effects of severe hypoglycemia on
cognitive function in school-aged children with diabetes
over 18 months. Diabetes Care 2003; 26: 1100-5.
27. Brands A, Kessels R, Hoogma R, et al. Cognitive
performance, psychological well-being, and brain
magnetic resonance imaging in older patients with type 1
diabetes. Diabetes 2006; 55: 1800-6.
Normalization of the Verbal Fluency Test 446 Arch Med Sci 3, June / 2010
28. Yeung SE, Fischer AL, Dixon RA. Exploring effects of type 2
diabetes on cognitive functioning in older adults.
Neuropsychology 2009; 23: 1-9.
29. Gallacher J, Pickering J, Elwood P, Bayer A, Yarnell J, Ben-
Shlomo Y. Glucoregulation has greater impact on
cognitive performance than macro-vascular disease in
men with type 2 diabetes: data from the Caerphilly study.
Eur J Epidemiol 2005; 20: 761-8.
30. Kanaya A, Barrett-Connor E, Gildengorin G, Yaffe K.
Change in cognitive function by glucose tolerance status
in older adults: a 4-year prospective study of the Rancho
Bernardo Study Cohort. Arch Int Med 2004; 164: 1327-33.
Adam Wysokiński, Krzysztof Zboralski, Agata Orzechowska, Piotr Gałecki, Antoni Florkowski, Monika Talarowska 